More Pressure On Pharma: UN Report Backs Compulsory Licensing
Executive Summary
Heavy-weight United Nations panel makes tough recommendations favoring compulsory licensing – an issue that has riled Big Pharma but has at least one industry proponent, Cipla's chair Yusuf Hamied, who talked to the Pink Sheet about the "excesses" of intellectual property rights.
You may also be interested in...
Patent Prognosis: Pfizer’s Chief IP Counsel On The Year Ahead
For the biopharma industry, nothing is more important than patent protection in preserving that vital license to operate, especially now that IP is a key component of the global supply chain. Pfizer’s chief IP counsel Roy F. Waldron provides an overview of industry strengths and vulnerabilities – and what to do about them – as the IP policy front moves forward in 2017.
India's Proposed Tweak Of New Drug Rules: Bridge To Data Exclusivity?
A key Indian advisory panel is expected to consider a crucial tweak to certain regulations pertaining to the approval of “new drugs”, which domestic firms allege could facilitate a different form of data exclusivity and also limit competition.
Will UN Report On Access To Medicines Change Anything?
Industry opposes interference with intellectual property rights but is open to compulsory licensing and delinking R&D cost to drug prices in limited situations.